American Society of Hirudotherapy

Recurrent Trigger Finger (Post-Injection Failure)

Investigational use for trigger finger recurrent after corticosteroid injection failure; pre-surgical alternative explored in case series.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for trigger finger. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for recurrent trigger finger is investigational.
What evidence exists?
Tier C (investigational). Only case-series-level evidence; there are no randomized controlled trials. Evidence-based therapy for recurrent trigger finger after corticosteroid injection failure: repeat corticosteroid injection (limited to 2-3 total), percutaneous A1 pulley release, or open surgical release (high success rate >90 percent, ASSH-endorsed). Diabetes increases recurrence and decreases injection response.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the palm and finger for 5 to 14 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Worsening of triggering after the procedure (transient)
  • Risk if a leech is placed too close to digital nerves or flexor tendon sheath
  • Permanent small scars at bite sites on the palm
  • Delay of definitive A1 pulley release surgery which has >90 percent success
Who should not consider this
  • Patients with finger contracture or fixed locked-in flexion (surgical release needed)
  • Patients within 4 weeks of corticosteroid injection at the site
  • Patients with active flexor tendon sheath infection (surgical emergency)
  • Patients with diabetic neuropathy of the hand
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not been offered A1 pulley release surgery
What to ask your clinician
  • Have I been offered A1 pulley release surgery (>90 percent success)?
  • Have I had repeat corticosteroid injection (up to 2-3 total)?
  • If I have diabetes, is my glycemic control optimized?
  • What evidence specifically supports leech therapy for trigger finger?
  • What is the practitioner's experience with leech placement on the palm?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Sudden inability to flex or extend the finger (possible tendon rupture)
  • Severe palm pain with fever (rule out flexor tendon sheath infection — surgical emergency)
  • Spreading redness, warmth, pus, or red streaks (cellulitis or pyogenic flexor tenosynovitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for trigger finger.
  • Case-series evidence does NOT establish efficacy versus A1 pulley release surgery (>90 percent success) or repeat corticosteroid injection.
  • It does NOT cure trigger finger — recurrence is high without definitive treatment.
  • It does NOT substitute for surgical release in fixed locked-in flexion.
  • It does NOT address diabetes, which is the strongest recurrence risk factor.

Clinical Profile

Category
musculoskeletal
ICD-10
M65.30, M65.311, M65.312, M65.321, M65.322
Safety tier
low

Evidence Summary

A substantial minority of trigger fingers recur after a first corticosteroid injection. No controlled clinical trial or case series of leech therapy for trigger finger has been published; use is investigational and mechanistic only, with a hypothesized anti-inflammatory effect on flexor tenosynovial swelling. Standard alternatives include a second corticosteroid injection, percutaneous release, or open A1 pulley release. This entry addresses recurrent (post-injection) presentations and is distinct from the primary first-presentation trigger-finger entry.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Bhatia A et al. (2021), n=14

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active local infection
  • Recent (<4 weeks) local corticosteroid injection
  • Locked finger requiring acute surgical release

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Recurrent Trigger Finger (Post-Injection Failure) — Hirudotherapy Evidence | ASH